FDA has granted Roche a public hearing to defend the effectiveness of Avastin in breast cancer, reports the Associated Press. Several months ago, the regulatory agency said the drug was "ineffective" in breast cancer — it's currently approved to treat colon, lung, kidney, and brain cancer — and in December, FDA began the process to revoke the drug's approval, AP adds. Roche's hearing is scheduled for June 28. The company's decision to challenge the ruling is "rare," AP says, and the meeting in June will be "the first of its kind."
Sticking Up for Avastin
Feb 25, 2011